Stock Groups

GSK announces $1.25 billion settlement between ViiV Healthcare, Gilead -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILEPHOTO: This view depicts GlaxoSmithKline’s headquarters in London (Britain), January 17, 2022. REUTERS/Hannah McKay

(Reuters) – GlaxoSmithKline PLC has announced a $1.25 Billion settlement between ViiV Healthcare (NYSE:) and Gilead Sciences Inc (NASDAQ) On Tuesday Gilead’s Biktarvy was accused of patent violations. The Biktarvy is a medicine that treats human immunodeficiency viruses.

GSK reported that Gilead and the two companies reached an agreement to license the patent. Gilead will pay a 3 percent royalty on any future U.S. Biktarvy purchases.

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]